Atelerix signs exclusive China distribution deal
28 Apr 2025
Newcastle-based biotech company Atelerix has signed an exclusive distribution agreement with China’s supply chain and logistics organisation MineBio.
The Chinese firm will act as sole distribution partner for Atelerix products in China, that enable storage and transport of temperature-sensitive biomaterials without freezing.
Atelerix’s patented hydrogels physically encapsulatecells, stabilise membrane integrity, and preserve biological function during transport, avoiding problems associated with the ultra-cold chain and cryopreservation, states the company.
In 2024, it is estimated that China accounted for 37% of total global clinical trials conducted that year, with demand for advanced in vitro models and biomaterials, expected to grow.
“There is a burgeoning demand for high-quality, fresh biospecimens and sophisticated in vitro models in China,” said Atelerix CEO Alastair Carrington (pictured).
“[The] partnership with MineBio officially marks Atelerix's strategic entry into this market, and at an important time where the world is demanding broader access to advanced therapies – cell and gene therapies, for example.”
